Ishikura Satoshi, Nihei Keiji, Ohtsu Atsushi, Boku Narikazu, Hironaka Shuichi, Mera Kiyomi, Muto Manabu, Ogino Takashi, Yoshida Shigeaki
Radiation Oncology Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan.
J Clin Oncol. 2003 Jul 15;21(14):2697-702. doi: 10.1200/JCO.2003.03.055.
To assess the long-term toxicity after definitive chemoradiotherapy (CRT) for squamous cell carcinoma (SCC) of the esophagus.
Patients newly diagnosed with SCC of the esophagus and treated with definitive CRT between 1992 and 1999 in our institution were recruited from our database on the basis of the following criteria: age </= 75 years, performance status (PS; based on the Eastern Cooperative Oncology Group scale) 0 to 2, and clinical tumor-node-metastasis system stage I to IVA. The CRT consisted of two cycles of cisplatin 40 mg/m2 on days 1 and 8, and continuous infusion of fluorouracil 400 mg/m2/d on days 1 to 5 and 8 to 12, repeated every 5 weeks with concurrent radiotherapy of 60 Gy in 30 fractions. For the assessment of toxicity, the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme was adopted.
A total of 139 patients were recruited, and their characteristics were as follows: median age, 62 years (range, 38 to 75 years); 121 males and 18 females; 96 patients PS 0, 42 patients PS 1, and one patient PS 2; 15 patients T1, 11 patients T2, 60 patients T3, and 53 patients T4; and 101 patients M0, 38 patients M1a. With a median follow-up of 53 months, the median survival time and 5-year survival rate were 21 months and 29%, respectively. Of 78 patients with complete remission, two patients died as a result of acute myocardial infarction. Grade 2, 3, and 4 late toxicities occurred with the following incidences: pericarditis in eight patients, seven patients, and one patient, respectively; heart failure in zero, zero, and two patients; pleural effusion in seven, eight, and zero patients; and radiation pneumonitis in one patient, three patients, and zero patients, respectively.
Definitive CRT for SCC of the esophagus is effective with substantial toxicities. Additional investigation to minimize the normal tissue toxicities is warranted.
评估食管鳞状细胞癌(SCC)根治性放化疗(CRT)后的长期毒性。
从我们机构1992年至1999年期间新诊断为食管SCC并接受根治性CRT治疗的患者数据库中,根据以下标准招募患者:年龄≤75岁,体能状态(PS;基于东部肿瘤协作组量表)0至2,临床肿瘤-淋巴结-转移系统分期I至IVA。CRT方案包括第1天和第8天给予顺铂40mg/m²共两个周期,第1至5天和第8至12天持续输注氟尿嘧啶400mg/m²/天,每5周重复一次,同时进行60Gy分30次的放疗。为评估毒性,采用了放射肿瘤学组/欧洲癌症研究与治疗组织的晚期放射损伤评分方案。
共招募了139例患者,其特征如下:中位年龄62岁(范围38至75岁);男性121例,女性18例;96例患者PS为0,42例患者PS为1,1例患者PS为2;15例患者为T1期,11例患者为T2期,60例患者为T3期,53例患者为T4期;101例患者M0,38例患者M1a。中位随访53个月,中位生存时间和5年生存率分别为21个月和29%。在78例完全缓解的患者中,2例因急性心肌梗死死亡。2级、3级和4级晚期毒性发生的发生率如下:心包炎分别为8例、7例和1例;心力衰竭分别为0例、0例和2例;胸腔积液分别为7例、8例和0例;放射性肺炎分别为1例、3例和0例。
食管SCC的根治性CRT有效,但毒性较大。有必要进一步研究以尽量减少正常组织毒性。